Health Catalyst, Inc. (HCAT) AI Stock Analysis

Health Catalyst, Inc. provides advanced data and analytics technology tailored specifically for healthcare organizations. Its platform integrates artificial intelligence and data science capabilities to improve operational efficiencies, clinical outcomes, and patient care experiences. In addition to traditional business intelligence tools enhanced with AI-driven analytics, the company offers population health management solutions featuring automated workflows. Health Catalyst also provides financial transformation applications focused on costing, labor productivity, and revenue capture, as well as solutions for quality and safety improvement supported by clinical data and expert services.

Annual revenue grew from $241.9M in FY2021 to $311.1M in FY2025, reflecting a 5-year revenue CAGR of 10.5% from FY2020 to FY2025. However, year-over-year revenue growth slowed from 28.1% in FY2021 to 1.5% in FY2025. Gross margin contracted to 33.5% in FY2025 from 48.6% in FY2021, while operating margin improved from -59.4% in FY2021 to -11.6% in FY2025. Net income stood at -$178.0M in FY2025. In the trailing twelve months, revenue reached $292.2M with an operating margin of -5.3% and a profit margin of -90.6%. For the latest quarter ended June 30, 2026, revenue declined 12.7% year-over-year.

As of June 30, 2026, Health Catalyst held $103.4M in cash and short-term investments against total debt of $170.0M, resulting in net debt of $66.5M. Total assets were $358.6M and shareholders' equity was $100.8M, yielding a debt-to-equity ratio of 1.69 and a current ratio of 2.70. In FY2025, operating cash flow was $731,000 and free cash flow was -$237,000. Capital expenditures were $968,000, and the company completed $5.0M in share buybacks in FY2025, while its share count increased 41.9% over 5 years.

Health Catalyst has a market capitalization of $129.8M and an enterprise value of $196.8M. The stock trades at a forward P/E of 10.0x and a price-to-sales ratio of 0.4x, below the median of its US-listed Healthcare peers, which have a forward P/E of 17.3x and a price-to-sales ratio of 4.1x. Its EV-to-revenue ratio stands at 0.7x, and price-to-book is 1.3x. Over the past year, HCAT shares returned -44.2% compared to a 16.8% return for the S&P 500 (SPY), and the stock has returned -96.4% over 5 years versus 83.0% for the index.

Wall Street coverage includes 1 Strong Buy and 4 Hold ratings. The mean price target is $1.77, representing a 2.4% upside compared to the last close of $1.73 on October 16, 2026. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.04 and revenue of $247.8M. For the next fiscal year, 4 analysts estimate an EPS of $0.01 on revenue of $205.5M, reflecting a projected revenue decline of 17.1%. Over the last four quarters, the company beat EPS estimates 1 time. The next earnings date is November 9, 2026.

This page is an AI-written research summary of Health Catalyst, Inc. (HCAT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HCAT income statement, HCAT balance sheet, HCAT key metrics, HCAT analyst forecast, HCAT chart. See the HCAT stock overview for the latest quote and news.